<DOC>
	<DOCNO>NCT03029247</DOCNO>
	<brief_summary>This open-label , randomize , parallel-group study hemodialysis-dependent ( HD ) subject anemia associate chronic kidney disease ( CKD ) , design compare effect daprodustat epoetin alfa blood pressure ( BP ) . After 4-week screen 4-week erythropoesis-stimulating agent ( ESA ) washout period , Day 1 subject randomize 1:1 stratified prior ESA dose undergo Acute Challenge 1 , single dose challenge compare acute effect BP high plan once-daily maintenance dose daprodustat ( 24 milligram [ mg ] ) high start dose epoetin alfa ( 100 international unit [ IU ] /kilograms [ kg ] ) . This follow 8-week hemoglobin ( Hgb ) -maintenance period , dose either daprodustat epoetin alfa administer adjust . At end Hgb maintenance period , Day 57 Acute Challenge ( number 2 ) repeat utilizing treatment Acute Challenge 1 ; follow-up visit within 14+/-3 day complete treatment . The total duration subject involvement 18 week ( Screening Follow-up ) .</brief_summary>
	<brief_title>A Phase IIA Study Blood Pressure Comparing Daprodustat Erythropoiesis-stimulating Agent Subjects With Anemia Chronic Kidney Disease Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>Inclusion Criteria More equal 40 year age , time signing informed consent Stable Hgb 9.0 11.5 gram per deciliter ( g/dL ) inclusive . Dialysis frequency : On hemodialysis ( HD , hemofiltration hemodiafiltration ) threeto fivetimes weekly least 4 week prior screen . A single pool Kt/Vurea &gt; =1.2 base historical value obtain within 3 month prior screen order ensure adequacy dialysis . If Kt/Vurea available , average last 2 value urea reduction ratio least 65 % . Treated ESA ( epoetins biosimilars , darbepoetin , methoxy polyethylene glycol [ PEG ] epoetin beta ) total weekly dose vary &gt; 50 % 4 week prior screen . Subjects may stable maintenance oral intravenous ( IV ; &lt; =100 mg/week ) iron supplementation . If subject oral IV iron , dose must stable 4 week prior screen Day 1 . Estimated Dry Weight : Midweek average weight gain dialysis treatment &lt; 5 % assessed pre postdialysis screen Day 1 . On least 2 different antihypertensive medication different class stable dose number hypertensive medication 4 week prior screen Day 1 . Capable give sign informed consent , include compliance requirement restriction list consent form protocol . Willing able wear ABPM device least 25 hour two separate session Exclusion Criteria Planned change HD peritoneal dialysis within study time period , home dialysis . Planned kidney transplant within 18 week follow Screening visit . An epoetin alfa dose &gt; =360 International unit ( IU ) /Kilograms ( kg ) /week IV &gt; =250 IU/kg/week subcutaneous ( SC ) , darbepoetin dose &gt; =1.8 microgram ( μg ) /kg/week IV SC , methoxy PEGepoetin beta dose &gt; =2.2 μg/kg/week within 8 week prior screen Week 4 . Administration Mircera ( methoxy PEGepoetin beta ) within 4 week prior screen Week 4 . Occurrence myocardial infarction acute coronary syndrome within 4 week prior screen Day 1 . Stroke transient ischemic attack within 4 week prior screen Day 1 . Chronic Class IV heart failure , define New York Heart Association functional classification system diagnose prior screen Day 1 . QT interval correct heart rate use Bazett 's formula ( QTcB ) &gt; 500 millisecond ( msec ) , QTcB &gt; 530 msec subject Bundle Branch Block . There QTc exclusion subject predominantly pace rhythm . Resting SBP &gt; 160 millimeter mercury ( mmHg ) ; DBP &gt; 100 mmHg screening . Presence atrial fibrillation history atrial fibrillation Active chronic inflammatory disease could impact erythropoiesis ( e.g. , scleroderma , systemic lupus erythematosus , rheumatoid arthritis , celiac disease ) diagnose prior screen Day 1 . History bone marrow aplasia pure red cell aplasia . Other cause anemic include Pernicious anemia , thalassemia major , sickle cell disease myelodysplastic syndrome . Alanine transaminase ( ALT ) &gt; 2x upper limit normal ( ULN ) ( screen ) Bilirubin &gt; 1.5xULN ( screen ) Current unstable liver biliary disease per investigator assessment , generally define presence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , esophageal gastric varix , persistent jaundice , cirrhosis . Major surgery ( exclude vascular access surgery ) within 8 week prior screen Day 1 , plan study . Blood transfusion within 8 week prior screen Day 1 , anticipate need blood transfusion study . Evidence actively bleed gastric , duodenal , esophageal ulcer disease OR clinically significant gastrointestinal bleeding within 4 week prior screen Day 1 . Clinical evidence acute infection history infection require IV antibiotic therapy within 4 week prior Screening Day 1 . History malignancy within two year prior screen Day 1 currently receive treatment cancer , know complex kidney cyst ( e.g. , Bosniak Category IIF , III IV ) &gt; =3 centimeter . Subjects upper arm diameter measure oscillometer/ sphygmomanometer cuff OR BP measure opposite arm current vascular access . History severe allergic anaphylactic reaction hypersensitivity excipients investigational product . Use prescription nonprescription drug dietary supplement prohibit screen Day 1 . The subject participate clinical trial receive experimental investigational product within 30 day prior screen Day 1 . Any condition , clinical laboratory abnormality , examination find investigator considers would put subject unacceptable risk , may affect study compliance prevent understand aim investigational procedure possible consequence study . A female subject pregnant ( confirm positive serum human chorionic gonadotrophin test female reproductive potential ) , subject breastfeeding , subject reproductive potential agree follow one prespecified contraceptive option Vitamin B12 low limit reference range ( may rescreen minimum 8 week ) . Folate &lt; 2.0 nanogram ( ng ) /milliliter ( mL ) ( 4.5 Nanomoles/L ) ( may rescreen minimum 4 week ) . Ferritin &lt; 100 ng/mL Transferrin saturation &lt; 20 % .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Daprodustat</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>ESA</keyword>
	<keyword>CKD</keyword>
</DOC>